Aviva’s Axonics, Inc. Common Stock AXNX Stock Holding History

Aviva’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,788	Closed	-$1.3M	–	993
2021 Q1	$1.3M	Sell	21,788 -6,856	-24%	-$373K	0.01%	751
2020 Q4	$1.43M	Sell	28,644 -23,220	-45%	-$1.09M	0.01%	783
2020 Q3	$2.65M	Sell	51,864 -14,336	-22%	-$598K	0.02%	584
2020 Q2	$2.32M	Buy	+66,200	New	+$2.28M	0.01%	658

Other funds holding AXNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Aviva's AXNX Position: Q2 2021 in Review

Aviva sold out of Axonics, Inc. Common Stock (AXNX) in Q2 2021, closing a stake of 21,788 shares — an estimated $1.3M sold.

Aviva first reported a position in AXNX in Q2 2020 and held it in 4 quarters. The position peaked at $2.65M in Q3 2020. 177 funds tracked by Wall St. Rank hold AXNX as of Q2 2021.

Aviva reported no remaining Axonics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Aviva sold 21,788 Axonics, Inc. Common Stock shares in Q2 2021, an estimated $1.3M.
Aviva first reported a position in Axonics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
Aviva's Axonics, Inc. Common Stock position peaked at $2.65M in Q3 2020.
177 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.